Core Insights - The health care sector has several oversold stocks that present buying opportunities for undervalued companies [1] Group 1: Oversold Stocks - Travere Therapeutics Inc (NASDAQ:TVTX) has an RSI of 29.7, with a stock price decline of approximately 23% over the past month and a 52-week low of $12.91 [6] - Hims & Hers Health Inc (NYSE:HIMS) has an RSI of 29.7, with a stock price decline of around 13% over the past month and a 52-week low of $23.97 [6] - Enovis Corp (NYSE:ENOV) has an RSI of 29.6, with a stock price decline of about 14% over the past five days and a 52-week low of $22.98 [6] Group 2: Analyst Ratings and Price Targets - Evercore ISI Group initiated coverage on Hims & Hers Health with an In-Line rating and a price target of $33 [6] - BTIG analyst initiated coverage on Enovis with a Buy rating and a price target of $41 [6] - Travere Therapeutics' new PDUFA target action date for Filspari is set for April 13 [6]

Core Insights - CorMedix (CRMD) and Mirum Pharmaceuticals (MIRM) attract investors in the rare-disease biotech sector due to smaller patient populations that can yield significant revenue through premium pricing and regulatory incentives [1] - Both companies benefit from clearer clinical endpoints and faster regulatory pathways, allowing quicker market entry compared to traditional drugs [1] CorMedix (CRMD) Overview - CorMedix's lead product, DefenCath, received FDA approval in late 2023 as the first antimicrobial catheter lock solution in the U.S., aimed at reducing catheter-related bloodstream infections in kidney failure patients [2] - DefenCath generated $167.6 million in net sales in the first nine months of 2025, indicating strong market adoption [7] - The company plans to expand DefenCath's label into total parenteral nutrition and has diversified its revenue through a $300 million acquisition of Melinta Therapeutics, adding seven approved therapies to its portfolio [7] - Despite initial success, CorMedix's future outlook is cautious, with 2026 revenue guidance of $300-$320 million and projected 2027 revenues of $100-$140 million, reflecting pricing pressures and limited growth [8][11] Mirum Pharmaceuticals (MIRM) Overview - Mirum's lead product, Livmarli, is approved for treating cholestatic pruritus in patients with Alagille syndrome and has seen a 70% year-over-year increase in net sales, reaching $161.4 million in the first nine months of 2025 [3][12] - The company has expanded its portfolio with a new tablet formulation of Livmarli and additional bile acid products from the acquisition of Travere Therapeutics, generating $118.8 million in the first nine months of 2025 [16] - MIRM's revenue guidance for 2026 is approximately $630-$650 million, supported by a broader product base and ongoing clinical studies for new therapies [16][28] Comparative Analysis - Both companies exhibit a similar risk-reward profile, but MIRM presents a clearer growth narrative with multiple revenue drivers, while CRMD's outlook is clouded by conservative guidance and reliance on a single product [4][9] - MIRM's shares have increased by 75.3% over the past six months, contrasting with CRMD's 38% decline, indicating market preference for MIRM's growth potential [23] - Valuation metrics show MIRM trading at a price/book ratio of 16.02, significantly higher than CRMD's 1.43, reflecting investor confidence in MIRM's growth prospects [24] Investment Recommendation - Mirum Pharmaceuticals is viewed as the better investment opportunity due to its strong sales growth, diversified revenue streams, and multiple growth levers, while CorMedix faces more uncertainty and competitive pressures [25][29]

Company Overview - Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for individuals with rare kidney and metabolic diseases in the United States [2] Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws related to Travere, specifically whether the company and its executives made materially false or misleading statements or omitted important information regarding its business and operations [1][2] Law Firm Background - Robbins Geller is recognized as one of the leading law firms in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in securities-related class action cases in 2024, which is more than the next five law firms combined [3] - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years for providing the most monetary relief to investors [3]

Core Insights - Holzer & Holzer, LLC is investigating whether Travere Therapeutics, Inc. complied with federal securities laws following the FDA's extension of the review timeline for its supplemental New Drug Application for FILSPARI® in focal segmental glomerulosclerosis, which led to a drop in the company's stock price [1] Company Summary - Travere Therapeutics, Inc. disclosed on January 13, 2026, that the FDA has extended the review timeline for its supplemental New Drug Application for FILSPARI® [1] - The announcement resulted in a decline in the company's stock price [1] Legal Context - Holzer & Holzer, LLC is a law firm that specializes in representing shareholders and investors in litigation, including shareholder class action and derivative litigation [3] - The firm has a history of recovering hundreds of millions of dollars for shareholders affected by corporate misconduct since its founding in 2000 [3]

Core Viewpoint - Shares of Travere Therapeutics (TVTX) declined by 14.6% following the FDA's announcement to extend the review timeline for the supplemental new drug application (sNDA) for Filspari in the FSGS indication by three months, with a new decision date set for April 13, 2026 [1][7]. FDA Review Extension - The FDA extended the review timeline after Travere submitted additional information to better define the clinical benefit of Filspari, classifying these submissions as a major amendment to the sNDA [2]. - No new safety or manufacturing data was requested by the FDA for Filspari [2]. Product Information - Filspari is currently approved to slow kidney function decline in adults with primary IgA nephropathy at risk of disease progression [3]. - FSGS is a rare kidney disorder affecting over 40,000 patients in the U.S. and a similar number in the EU, characterized by progressive kidney scarring and proteinuria [5][8]. - If approved for FSGS, Filspari would be the first FDA-approved therapy for this condition, addressing podocyte injury, a critical factor in FSGS progression [8]. Market Performance - Over the past six months, Travere Therapeutics' shares have increased by 72.1%, outperforming the industry average increase of 20.4% [4]. Financial Projections - Preliminary sales for Q4 2025 are expected to be around $127 million, with full-year 2025 net product sales projected at approximately $410 million in the U.S. [10]. - Preliminary U.S. net product sales of Filspari for Q4 2025 are estimated at $103 million, reflecting a 108% year-over-year increase, with full-year sales around $322 million [11]. Partnerships and Future Plans - In October 2025, Travere received a $40 million milestone payment from CSL Vifor after achieving market access milestones, with further payments expected tied to additional market access and sales [12]. - The company plans to continue building clinical evidence to support Filspari as a foundational treatment for IgAN through ongoing clinical studies, with the potential label expansion for FSGS likely to boost sales in 2026 [13].

Company Overview - Travere Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for individuals with rare kidney and metabolic diseases in the United States [2]. Investigation Details - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws related to Travere, specifically whether the company and its executives made materially false and/or misleading statements or omitted important information regarding its business and operations [1][2]. Law Firm Background - Robbins Geller is recognized as one of the leading law firms in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in securities-related class action cases in 2024 alone, which is more than the next five law firms combined [3].

Core Viewpoint - The U.S. FDA has extended the review timeline for Travere Therapeutics' supplemental New Drug Application for FILSPARI® in the treatment of focal segmental glomerulosclerosis, with a new target action date set for April 13, 2026 [1] Group 1 - The FDA's extension follows the recent submission of additional responses requested to further characterize the clinical benefit of FILSPARI® [1]

Core Viewpoint - Travere Therapeutics Inc's stock is experiencing a significant decline due to new FDA questions regarding its Filspari application, overshadowing strong fourth-quarter sales performance [1] Group 1: Stock Performance - The stock is down 32.8%, trading at $22.92, marking its largest single-day percentage loss since September 2023 [1][2] - Today's decline has brought the stock to its lowest levels since September 2025, moving away from its record high of $42.03 reached on December 24 [2] - Year-over-year, the stock still maintains a 25.9% increase [2] Group 2: Options Activity - Options trading has surged, with 6,295 calls and 23,000 puts exchanged, which is 21 times the average daily options volume [3] - The most popular option is the January 16, 2026, 17.50-strike put, with new positions being opened [3] - The stock has been placed on the short sell restricted (SSR) list today [3] Group 3: Market Sentiment - The put/call volume ratio for Travere Therapeutics is 1.49, indicating a higher than usual interest in puts, ranking above 93% of readings from the past year [4]

Core Viewpoint - Travere Therapeutics emphasizes its commitment to rare diseases, driven by personal connections among its team members, including the CEO, who is a rare cancer survivor [3]. Group 1: Company Overview - Travere Therapeutics is represented by CEO Eric Dube at the 44th Annual JPMorgan Healthcare Conference, highlighting the company's focus on rare diseases [1][2]. - The company adopts a patient-inspired approach in its operations, reflecting the personal experiences of its employees with rare diseases [3]. Group 2: Performance and Priorities - Travere announced updates regarding its performance expectations for 2025 and outlined three key priorities for the company [4].

Summary of Travere Therapeutics FY Conference Call Company Overview - **Company**: Travere Therapeutics (NasdaqGM:TVTX) - **Event**: 44th Annual J.P. Morgan Healthcare Conference - **Date**: January 12, 2026 - **CEO**: Eric Dube Key Points Industry and Company Focus - Travere Therapeutics is focused on rare diseases, particularly in the areas of IgA nephropathy, FSGS (Focal Segmental Glomerulosclerosis), and homocystinuria (HCU) [2][3][32] Financial Performance - Achieved **$410 million** in net revenue for 2025, with **143% growth** compared to 2024 [3][4] - Revenue breakdown: **$323 million** from Filspari and **$88 million** from the Thiola portfolio [4] - **$103 million** revenue in Q4 2025, representing **108% growth** year-over-year [13] Product Updates - **Filspari**: - Reached an all-time high of **908 new patient start forms** in Q4 2025 for IgA nephropathy [3][12] - Positioned as a foundational therapy for IgA nephropathy, with a unique once-a-day pill formulation [10][11] - Clinical data shows a **50% reduction** in proteinuria compared to the standard of care [25] - Anticipated FDA approval for FSGS, with ongoing regulatory engagement [5][6][30] - **HARMONY Study**: - Phase III program for HCU reinitiated, focusing on enzyme replacement therapy [4][32] - Current treatment options are limited, with a significant unmet need for disease-modifying therapies [33] Regulatory Engagement - Ongoing discussions with the FDA regarding the FSGS supplemental new drug application (SNDA) [5][6] - Received additional information requests from the FDA focused on clinical benefits of Filspari, not related to safety or manufacturing [5][41] Market Opportunity - Approximately **70,000 patients** diagnosed with IgA nephropathy in the U.S., with a significant number still untreated [10] - Filspari is expected to capture a larger market share as awareness and clinical use grow [30][17] - The company has not yet reached **10%** of the addressable population for IgA nephropathy, indicating substantial growth potential [16][17] Clinical Insights - The KDIGO guidelines have been updated to reflect the urgency of treating IgA nephropathy, emphasizing the need for earlier intervention [9][15] - The PARASOL Group's findings indicate that reducing proteinuria is critical for lowering the risk of kidney failure in FSGS patients [21][23] Future Outlook - Travere is committed to redefining the standard of care in IgA nephropathy, FSGS, and HCU, with a strong financial foundation to support ongoing initiatives [37][52] - The company is prepared for rapid uptake of Filspari in FSGS upon approval, leveraging existing relationships with nephrologists [30][31] Patient-Centric Approach - The company emphasizes a patient-inspired approach, with personal connections to rare diseases among its team members [2] - Highlighted the story of a patient, Jennifer, to illustrate the impact of FSGS and the need for innovative therapies [38][39] Additional Important Information - The company has a strong commitment to the rare disease community and aims to provide hope and better treatment options for patients [39][52] - The upcoming PDUFA date for FSGS is critical, with expectations for timely communication regarding FDA decisions [40][41]